Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 2,492 |
|
|||||
| News | - | ||||||
| Day High | 5.13 | Low High |
|||||
| Day Low | 5.033 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ImmuCell Corporation | ICCC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 5.05 | 16:03:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.033 | 5.033 | 5.13 | 5.05 | 5.05 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 59 | 2,492 | $ 5.05 | $ 12,581 | - | 4.34 - 6.05 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 9 | $ 5.03 | USD |
ImmuCell Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 39.14M | 7.75M | - | 17.47M | -5.78M | -0.75 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ImmuCell News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ICCC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.20 | 5.20 | 5.0001 | 5.07 | 10,776 | -0.15 | -2.88% |
| 1 Month | 5.09 | 5.44 | 4.99 | 5.18 | 8,922 | -0.04 | -0.79% |
| 3 Months | 5.14 | 5.64 | 4.66 | 5.17 | 7,487 | -0.09 | -1.75% |
| 6 Months | 4.85 | 5.64 | 4.34 | 4.96 | 9,798 | 0.20 | 4.12% |
| 1 Year | 4.83 | 6.05 | 4.34 | 5.06 | 11,177 | 0.22 | 4.55% |
| 3 Years | 8.74 | 11.06 | 4.34 | 7.25 | 10,645 | -3.69 | -42.22% |
| 5 Years | 6.04 | 13.20 | 1.71 | 6.70 | 17,224 | -0.99 | -16.39% |
ImmuCell Description
| ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The firm has developed products that provide immediate immunity to newborn dairy and beef cattle and is developing product line extensions of its existing products that address mastitis. Its lead product, First Defense, is manufactured to prevent scours in newborn calves. The company generates the majority of its revenue from the United States. |
